{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:02:15Z","timestamp":1790262135141,"version":"4.1.0"},"reference-count":46,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n                  JAK2V617F-mutated myeloproliferative neoplasms (MPN) exhibit abnormal proliferation of bone marrow progenitors and increased risk of thrombosis, specifically in splanchnic veins (SVT). The contribution of the endothelium to the development of the prothrombotic phenotype was explored.<\/jats:p><jats:p>Plasma and serum samples from JAK2V617F MPN patients with (n=26) or without (n=7) thrombotic debut and different treatments, were obtained (n=33). Cultured endothelial cells (ECs) were exposed to serum samples from these patients and from healthy donors as controls. Changes in markers of inflammation (VCAM-1, ICAM-1), cell permeability (VE-cadherin), production of VWF, extracellular matrix (ECM) reactivity, and activation of intracellular signaling pathways related to stress, proliferation, inflammation (Akt, p44\/42, IkBa), and JAK2\/STAT3 pathway, were assessed by immunofluorescence, flow adhesion, SDS-PAGE and immunoblot. Additionally, circulating markers of endothelial activation and damage (VWF, sVCAM-1, sTNFRI, thrombomodulin, angiopoietin-2, a2-antiplasmin activity, PAI-1) were evaluated in Patients' plasma.<\/jats:p><jats:p>The in vitro studies showed that EC exposure to MPN thrombotic patients' sera resulted in increased VCAM-1 and ICAM-1, and reduced VE-cadherin expression (p&lt;0.05) at the cell surface. Production and release of VWF to the ECM were higher (p&lt;0.05), with increased platelet adhesion after perfusing whole blood, being more noticeable in response to sera from non-treated patients. Furthermore, intracellular activation of Akt, p44\/42, IkBa and JAK2\/STAT3 was observed. Moreover, plasma levels of VWF, TNF-R1, VCAM-1, thrombomodulin, and angiopoietin-2 were higher in JAK2V617F+ MPN patients with thrombosis.<\/jats:p><jats:p>The present findings suggest that circulating factors in MPNs with SVT debut induce endothelial proinflammatory and prothrombotic phenotypes, which are modulated in vitro with MPN treatment.<\/jats:p>","DOI":"10.1055\/a-2498-4849","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T19:33:04Z","timestamp":1736883184000},"page":"1010-1022","source":"Crossref","is-referenced-by-count":12,"title":["Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis"],"prefix":"10.1055","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4500-3884","authenticated-orcid":false,"given":"Blanca","family":"De Moner","sequence":"additional","affiliation":[{"name":"Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagn\u00f2stic Biom\u00e8dic (CDB), Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain"},{"name":"Josep Carreras Leukaemia Research Institute, University of Barcelona, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"},{"name":"Barcelona Endothelium Team, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Martinez-Sanchez","sequence":"additional","affiliation":[{"name":"Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagn\u00f2stic Biom\u00e8dic (CDB), Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain"},{"name":"Barcelona Endothelium Team, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garrote","sequence":"additional","affiliation":[{"name":"Hematopathology Section, Pathology Department, Centre de Diagn\u00f2stic Biom\u00e8dic (CDB), Hospital Cl\u00ednic de Barcelona, IDIBAPS, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Ramos","sequence":"additional","affiliation":[{"name":"Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagn\u00f2stic Biom\u00e8dic (CDB), Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain"},{"name":"Barcelona Endothelium Team, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Ventosa-Capell","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Moreno-Casta\u00f1o","sequence":"additional","affiliation":[{"name":"Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagn\u00f2stic Biom\u00e8dic (CDB), Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain"},{"name":"Barcelona Endothelium Team, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Nomdedeu","sequence":"additional","affiliation":[{"name":"Hemostasis and Hemotherapy Department, Institut del C\u00e0ncer i Malalties de la Sang (ICAMS), Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Ojeda","sequence":"additional","affiliation":[{"name":"Liver Unit, Barcelona Hepatic Haemodynamic Laboratory, Hospital Cl\u00ednic de Barcelona, IDIBAPS and CIBERehd, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gines","family":"Escolar","sequence":"additional","affiliation":[{"name":"Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagn\u00f2stic Biom\u00e8dic (CDB), Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain"},{"name":"Barcelona Endothelium Team, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Carles","family":"Garcia-Pagan","sequence":"additional","affiliation":[{"name":"Liver Unit, Barcelona Hepatic Haemodynamic Laboratory, Hospital Cl\u00ednic de Barcelona, IDIBAPS and CIBERehd, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6236-7826","authenticated-orcid":false,"given":"Eduardo","family":"Arellano-Rodrigo","sequence":"additional","affiliation":[{"name":"Hemostasis and Hemotherapy Department, Institut del C\u00e0ncer i Malalties de la Sang (ICAMS), Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Carreras","sequence":"additional","affiliation":[{"name":"Barcelona Endothelium Team, Barcelona, Spain"},{"name":"Fundaci\u00f3 Carreras contra la Leuc\u00e8mia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Alvarez-Larran","sequence":"additional","affiliation":[{"name":"Hematology Department, Institut del C\u00e0ncer i Malalties de la Sang (ICAMS), Hospital Cl\u00ednic de Barcelona, IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"D\u00edaz-Ricart","sequence":"additional","affiliation":[{"name":"Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagn\u00f2stic Biom\u00e8dic (CDB), Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain"},{"name":"Barcelona Endothelium Team, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"09","key":"ref1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMc1708485","article-title":"Myeloproliferative neoplasms","volume":"377","author":"T Barbui","year":"2017","journal-title":"N Engl J Med"},{"issue":"07","key":"ref2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"W Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"7037","key":"ref3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"R L Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"ref5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"25","key":"ref6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"J Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2008.133","article-title":"Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders","volume":"22","author":"C Walz","year":"2008","journal-title":"Leukemia"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"T Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"A Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3324\/haematol.2018.205989","article-title":"New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches","volume":"104","author":"M Bar-Natan","year":"2019","journal-title":"Haematologica"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/stem.2229","article-title":"P-selectin sustains extramedullary hematopoiesis in the Gata1 low model of myelofibrosis","volume":"34","author":"G J Spangrude","year":"2016","journal-title":"Stem Cells"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/09537104.2013.840720","article-title":"Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis","volume":"25","author":"E Zetterberg","year":"2014","journal-title":"Platelets"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"B Edelmann","year":"2018","journal-title":"J Clin Invest"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/ijms22031143","article-title":"Emerging role of neutrophils in the thrombosis of chronic myeloproliferative neoplasms","volume":"22","author":"F Ferrer-Mar\u00edn","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.3390\/ijms24054497","article-title":"Putative role of neutrophil extracellular trap formation in chronic myeloproliferative neoplasms","volume":"24","author":"D C Markovi\u0107","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2009.013375","article-title":"Blood cell activation in myeloproliferative neoplasms","volume":"94","author":"F Cervantes","year":"2009","journal-title":"Haematologica"},{"issue":"02","key":"ref17","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"E Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2\u2009V617F allele burden","volume":"84","author":"E Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"A Guy","year":"2019","journal-title":"Haematologica"},{"issue":"15","key":"ref20","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"J Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1055\/s-0037-1616539","article-title":"Uremic medium disturbs the hemostatic balance of cultured human endothelial cells","volume":"86","author":"M Serradell","year":"2001","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref22","first-page":"149","article-title":"A rapid embedding procedure for the study of platelet interactions with extracellular matrices in a flowing system. Effect of aspirin on platelet activity","volume":"12","author":"J Aznar-Salatti","year":"1990","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"04","key":"ref23","first-page":"219","article-title":"Digital image analysis of platelet-extracellular matrix interactions: studies in von Willebrand disease patients and aspirin-treated donors","volume":"24","author":"M D\u00edaz-Ricart","year":"1994","journal-title":"Haemostasis"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"S L Etheridge","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features","volume":"118","author":"A Guadall","year":"2018","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"B D Manning","year":"2017","journal-title":"Cell"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2353\/ajpath.2008.070502","article-title":"Mechanisms and consequences of neutrophil interaction with the endothelium","volume":"172","author":"A Zarbock","year":"2008","journal-title":"Am J Pathol"},{"issue":"39","key":"ref28","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1038\/onc.2017.148","article-title":"STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression","volume":"36","author":"K J Kim","year":"2017","journal-title":"Oncogene"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"e885","DOI":"10.1097\/HS9.0000000000000885","article-title":"Impact of clonal architecture on clinical course and prognosis in patients with myeloproliferative neoplasms","volume":"7","author":"D Luque Paz","year":"2023","journal-title":"HemaSphere"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"987643","DOI":"10.3389\/fonc.2022.987643","article-title":"Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression","volume":"12","author":"A Malara","year":"2022","journal-title":"Front Oncol"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1038\/s41467-022-32928-3","article-title":"Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm","volume":"13","author":"M FU Rahman","year":"2022","journal-title":"Nat Commun"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"P Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jtha.2023.01.027","article-title":"JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions","volume":"21","author":"J D Beckman","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/09537104.2021.1934665","article-title":"Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function","volume":"33","author":"I Parra-Izquierdo","year":"2022","journal-title":"Platelets"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"104060","DOI":"10.1016\/j.mvr.2020.104060","article-title":"Ruxolitinib attenuates intimal hyperplasia via inhibiting JAK2\/STAT3 signaling pathway activation induced by PDGF-BB in vascular smooth muscle cells","volume":"132","author":"H T Song","year":"2020","journal-title":"Microvasc Res"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"S Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"ref37","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"C N Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis","volume":"27","author":"B T Samuelson","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"A Masciulli","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"ref40","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/cncr.34195","article-title":"Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea","volume":"128","author":"A Alvarez-Larr\u00e1n","year":"2022","journal-title":"Cancer"},{"issue":"07","key":"ref41","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood.V99.7.2297","article-title":"Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia","volume":"99","author":"M Benkerrou","year":"2002","journal-title":"Blood"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2141.2003.03849.x","article-title":"The role of hydroxyurea in sickle cell disease","volume":"120","author":"C Halsey","year":"2003","journal-title":"Br J Haematol"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/bjh.17650","article-title":"Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a longitudinal study","volume":"194","author":"L Elsherif","year":"2021","journal-title":"Br J Haematol"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"L C Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon-\u03b1 directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1","volume":"96","author":"Q Wang","year":"2000","journal-title":"Blood"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","article-title":"Interferon-\u03b1 targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway","volume":"38","author":"M Lu","year":"2010","journal-title":"Exp Hematol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2498-4849.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T23:10:09Z","timestamp":1758669009000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2498-4849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,23]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2498-4849","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}